Fibrinogen is a critical protein for hemostasis and clot formation. However, transfusion
guidelines have variable recommendations for maintaining fibrinogen levels in bleeding
patients. An increasing number of studies support the practice of fibrinogen replacement therapy for acquired coagulopathies,and additionalstudiesareunderway.
Fibrinogen therapy can be administered with cryoprecipitate or fibrinogen concentrates,
and clinical practice varies according to their availability and licensing status. Fibrinogen
concentrate therapy has been studied in animal models and clinical trials and supports
the critical role of fibrinogen repletion in bleeding patients. Point-of-care testing
will have an important role in guiding fibrinogen replacement for hemostatic therapy in clinical settings such as cardiovascular surgery, postpartum hemorrhage, and trauma. Fibrinogen therapy is an important component of a multimodal strategy for the treatment of coagulopathic bleeding. (Blood. 2015;125(9):1387-1393)
BLOOD, 26 FEBRUARY 2015 x VOLUME 125, NUMBER 9
